Axon Enterprise, Inc (NASDAQ:AXON) Position Increased by Vontobel Holding Ltd.

Vontobel Holding Ltd. grew its position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 73.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,736 shares of the biotechnology company's stock after purchasing an additional 2,860 shares during the period. Vontobel Holding Ltd.'s holdings in Axon Enterprise were worth $3,543,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Fourth Dimension Wealth LLC acquired a new stake in shares of Axon Enterprise in the fourth quarter worth approximately $30,000. Bartlett & CO. Wealth Management LLC boosted its position in shares of Axon Enterprise by 132.0% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 33 shares during the last quarter. Alpine Bank Wealth Management acquired a new stake in shares of Axon Enterprise in the first quarter worth approximately $40,000. Elequin Capital LP acquired a new stake in shares of Axon Enterprise in the fourth quarter worth approximately $46,000. Finally, CoreFirst Bank & Trust acquired a new stake in shares of Axon Enterprise in the fourth quarter worth approximately $59,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Trading Up 2.7%

NASDAQ AXON traded up $20.93 during mid-day trading on Friday, hitting $795.48. The company's stock had a trading volume of 268,670 shares, compared to its average volume of 540,118. Axon Enterprise, Inc has a 52-week low of $279.02 and a 52-week high of $830.21. The stock's fifty day simple moving average is $736.97 and its two-hundred day simple moving average is $635.97. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.83 and a quick ratio of 2.62. The firm has a market capitalization of $61.93 billion, a P/E ratio of 192.14, a price-to-earnings-growth ratio of 91.57 and a beta of 1.29.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. The company had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The business's quarterly revenue was up 31.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.15 earnings per share. Research analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. The Goldman Sachs Group raised their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th. Craig Hallum cut shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research report on Monday, March 10th. Needham & Company LLC raised their target price on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Bank of America raised their target price on shares of Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research report on Wednesday, June 4th. Finally, Barclays raised their price target on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat.com, Axon Enterprise presently has an average rating of "Moderate Buy" and an average target price of $699.55.

Insider Activity at Axon Enterprise

In related news, Director Michael Garnreiter sold 5,913 shares of Axon Enterprise stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $760.00, for a total value of $4,493,880.00. Following the completion of the sale, the director owned 17,740 shares in the company, valued at approximately $13,482,400. The trade was a 25.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CRO Cameron Brooks sold 3,000 shares of Axon Enterprise stock in a transaction on Friday, May 30th. The stock was sold at an average price of $740.76, for a total transaction of $2,222,280.00. Following the completion of the sale, the executive owned 19,447 shares of the company's stock, valued at approximately $14,405,559.72. This trade represents a 13.36% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 44,642 shares of company stock valued at $30,500,428. 4.40% of the stock is currently owned by corporate insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.